carbachol and brimonidine tartrate
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
YUVEZZI is a fixed-dose ophthalmic combination of carbachol (a cholinergic agonist) and brimonidine tartrate (an alpha-2 adrenergic agonist) delivered as a topical solution. It combines mechanisms to modulate intraocular pressure and ocular hemodynamics in glaucoma or ocular hypertension patients. The dual-agent formulation targets complementary pathways to optimize therapeutic effect in a single drop.
Early-stage launch with no direct competitors reported, creating significant growth opportunity for commercial teams to establish market presence and prescriber adoption.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
YUVEZZI launch creates immediate commercial career opportunities with 13 open positions concentrated in specialty sales and regional management roles across key markets. This is a growth-phase product with no LOE concerns for the next 16 years, offering stability and advancement potential in field sales, territory management, and account leadership.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
13 open roles linked to this drug
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo